基蛋生物12月26日获融资买入565.59万元，融资余额1.99亿元

Core Viewpoint - The financial performance of 基蛋生物 (Jidan Bio) shows a decline in revenue and net profit for the first nine months of 2025, indicating potential challenges in the company's growth trajectory [2]. Group 1: Financial Performance - For the period from January to September 2025, 基蛋生物 reported a revenue of 758 million yuan, representing a year-on-year decrease of 13.88% [2]. - The net profit attributable to shareholders for the same period was 161 million yuan, down 8.48% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 847 million yuan, with 391 million yuan distributed over the past three years [2]. Group 2: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for 基蛋生物 was 25,200, a decrease of 4.22% from the previous period [2]. - The average number of circulating shares per shareholder increased by 4.40% to 20,137 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 12.87 million shares, an increase of 7.10 million shares from the previous period [2]. Group 3: Financing and Trading Activity - On December 26, 基蛋生物's stock price increased by 0.60%, with a trading volume of 48.46 million yuan [1]. - The financing buy amount for the day was 5.66 million yuan, while the financing repayment was 8.06 million yuan, resulting in a net financing outflow of 2.41 million yuan [1]. - The total balance of margin trading for 基蛋生物 as of December 26 was 200 million yuan, with the financing balance accounting for 4.72% of the circulating market value [1].